NCT06524687View on ClinicalTrials.gov

A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies

PHASE1TerminatedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

May 29, 2024

Primary Completion Date

January 21, 2025

Study Completion Date

January 21, 2025

Conditions
Idiopathic Inflammatory MyopathiesInflammatory Myopathies
Interventions
DRUG

Imvotamab

Administered intravenously

Trial Locations (1)

94306

Standford University, Palo Alto

Sponsors
All Listed Sponsors
lead

IGM Biosciences, Inc.

INDUSTRY

NCT06524687 - A Study of Imvotamab in Active, Refractory Idiopathic Inflammatory Myopathies | Biotech Hunter | Biotech Hunter